{Reference Type}: Consensus Development Conference
{Title}: Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference.
{Author}: Baiocchi GL;D'Ugo D;Coit D;Hardwick R;Kassab P;Nashimoto A;Marrelli D;Allum W;Berruti A;Chandramohan SM;Coburn N;Gonzàlez-Moreno S;Hoelscher A;Jansen E;Leja M;Mariette C;Meyer HJ;Mönig S;Morgagni P;Ott K;Preston S;Rha SY;Roviello F;Sano T;Sasako M;Shimada H;Schuhmacher C;So Bok-Yan J;Strong V;Yoshikawa T;Terashima M;Ter-Ovanesov M;Van der Velde C;Memo M;Castelli F;Pecorelli S;Detogni C;Kodera Y;de Manzoni G;
{Journal}: Gastric Cancer
{Volume}: 19
{Issue}: 1
{Year}: Jan 2016
{Factor}: 7.701
{DOI}: 10.1007/s10120-015-0513-0
{Abstract}: <B>OBJECTIVE: </B>Presently, there is no scientific evidence supporting a definite role for follow-up after gastrectomy for cancer, and clinical practices are quite different around the globe. The aim of this consensus conference was to present an ideal prototype of follow-up after gastrectomy for cancer, based on shared experiences and taking into account the need to rationalize the diagnostic course without losing the possibility of detecting local recurrence at a potentially curable stage.<BR><B>METHODS: </B>On June 19-22, 2013 in Verona (Italy), during the 10th International Gastric Cancer Congress (IGCC) of the International Gastric Cancer Association, a consensus meeting was held, concluding a 6-month, Web-based, consensus conference entitled "Rationale of oncological follow-up after gastrectomy for cancer."<BR><B>RESULTS: </B>Forty-eight experts, with a geographical distribution reflecting different health cultures worldwide, participated in the consensus conference, and 39 attended the consensus meeting. Six statements were finally approved, displayed in a plenary session and signed by the vast majority of the 10th IGCC participants. These statements are attached as an annex to the Charter Scaligero on Gastric Cancer.<BR><B>CONCLUSIONS: </B>After gastrectomy for cancer, oncological follow-up should be offered to patients; it should be tailored to the stage of the disease, mainly based on cross-sectional imaging, and should be discontinued after 5 years.